Asthma Hay Fever Alcoholic cardiomyopathy Pregnancy Acne Malabsorption Soft Tissue Arthropathies Heart failure Hair Loss Amebic liver abscess Aortic regurgitation

Sepsis: A Background Guide

Source: www.lilly.com
Topic: Sepsis
Download: Click here!

Sort Desciption: A new drug offers hope in the treatment of a complex and devastating syndrome Introduction Every year, more than 750,000 people in the United States develop severe sepsis, a syndrome characterized by an overwhelming systemic ...

Content Inside:
A new drug offers hope in the treatment of a complex and devastating syndrome Introduction Every year, more than 750,000 people in the United States develop severe sepsis, a syndrome characterized by an overwhelming systemic response to infection that can rapidly lead to organ failure and ultimately death. 1 Sepsis may cause multiple organs in the body to fail, and can trigger the onset of both abnormal clotting and bleeding. Thirty percent of people with sepsis die from its consequences within the first month; up to 50 percent die within six months. 2, 3, 4 Formerly known as blood poisoning, 5 sepsis can strike anyone, but is most likely to develop from infection associated with events such as pneumonia, trauma, surgery, and burns, or serious illnesses such as cancer and AIDS. In fact, people whose deaths are ascribed to complications of cancer, AIDS, or pneumonia, often actually die as a direct result of sepsis. It is most commonly seen in critically ill hospitalized patients and, in the United States, is the leading cause of death in medical intensive care units. Until recently, there was no drug therapy specifically approved to treat sepsis; the only recourse was to provide supportive care and antibiotics for the underlying infection. A better understanding of the complex mechanisms of sepsis has led to the development of a breakthrough drug with the potential to save the lives of patients that would otherwise be lost to life-threatening severe sepsis. After decades of research on promising but ultimately ineffective medications, recombinant human activated protein C (drotrecogin alfa activated , or Xigris ® ) has emerged as the only drug with proven efficacy in treating life-threatening severe sepsis. Approved by the U.S. Food and Drug Administration in November 2001, Xigris has a proven 29 percent relative risk ...

Name (required)

E-mail (required - never shown publicly)

URI (optional)

Your Comment

Verification Code

© 2007-2008 HealthPDF.org | Design by Ganesh Gunasegaran
Privacy Policy

All files and contents mentioned are the property of their respective owners. This page consists of a compilation of public information, commonly available on the internet, at multiple sites, as well as official websites. No information on this page is guaranteed to be correct, and any data contained here may be erroneous.